Monday, July 28, 1997
FDA panel likes what it sees
BETHESDA, Md. - An FDA advisory panel on Friday enthusiastically endorsed the safety and efficacy of Idec Pharmaceuticals Corp.'s Rituxan (IDEC-C2B8) for the treatment of relapsed or refractory, low-grade and follicular non-Hodgkin's lymphoma (NHL).
In addition to its unanimous votes regarding safety and efficacy, the Biological Response Modifiers Advisory Committee (BRMAC) rejected FDA's suggestions regarding potential label limitations.